Breast cancer, neoadjuvant chemotherapy and residual disease

Clinical and Translational Oncology

Volumn 12, Issue 7, 2010, Pages 461-467

  Chávez Macgregor, Mariana ^a   González Angulo, Ana María ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Residual cancer burden; Residual disease

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IXABEPILONE; KI 67 ANTIGEN; METHOTREXATE; NAVELBINE; PROGESTERONE RECEPTOR; TRASTUZUMAB; ZOLEDRONIC ACID;

ADVANCED CANCER; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG TARGETING; GENE EXPRESSION; GENETIC MARKER; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL;

EID: 77956016989     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0538-0     Document Type: Review

References (49)

1. A. Jemal R. Siegel E. Ward, et al. 2008 Cancer statistics CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010 18287387
2. American Cancer Society 2009 Breast cancer facts and figures 2007-2008 American Cancer Society Atlanta American Cancer Society (2009) Breast cancer facts and figures 2007-2008 Atlanta: American Cancer Society. http://www.cancer.org/downloads/stt/bcff-final.pdf
3. SEER (2009) Cancer statistics review 1975-2006: National Cancer Institute, DC-CPS, Surveillance Research Program, Cancer Statistics Branch.
4. NCCN (2009) Clinical practice guidelines in oncology. Breast cancer V.I: National Comprehensive Cancer Network. http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp
5. B. Fisher J. Bryant N. Wolmark, et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 1:CAS:528:DyaK1cXlsFCgurg%3D 9704717
6. P. Rastogi S.J. Anderson H.D. Bear, et al. 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 778 785 10.1200/JCO.2007.15.0235 18258986
7. H.M. Kuerer L.A. Newman T.L. Smith, et al. 1999 Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 460 469 1:CAS:528:DyaK1MXht1Wmur4%3D 10080586
8. B.T. Hennessy G.N. Hortobagyi R. Rouzier, et al. 2005 Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy J Clin Oncol 23 9304 9311 10.1200/JCO.2005.02.5023 16361629
9. R. Rouzier J.M. Extra J. Klijanienko, et al. 2002 Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes J Clin Oncol 20 1304 1310 10.1200/JCO.20.5.1304 11870173
10. R.L. Jones S.R. Lakhani A.E. Ring, et al. 2006 Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma Br J Cancer 94 358 362 10.1038/sj.bjc.6602950 1:CAS:528: DC%2BD28XhtFGqs7c%3D 16421590
11. C. Mazouni F. Peintinger S. Wan-Kau, et al. 2007 Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome J Clin Oncol 25 2650 2655 10.1200/JCO.2006.08.2271 1:CAS:528: DC%2BD2sXosValt7s%3D 17602071
12. L. Pusztai 2008 Preoperative systemic chemotherapy and pathologic assessment of response Pathol Oncol Res 14 169 171 10.1007/s12253-008-9070-8 18553157
13. W.F. Symmans F. Peintinger C. Hatzis, et al. 2007 Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy J Clin Oncol 25 4414 4422 10.1200/JCO.2007.10.6823 17785706
14. I.C. Smith S.D. Heys A.W. Hutcheon, et al. 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456 1466 10.1200/JCO.20.6.1456 1:CAS:528:DC%2BD38XivFeisbg%3D 11896092
15. E. Thomas F.A. Holmes T.L. Smith, et al. 2004 The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial J Clin Oncol 22 2294 2302 10.1200/JCO.2004.05.207 1:CAS:528:DC%2BD2cXpsVWltLk%3D 15197190
16. G. von Minckwitz S. Kummel P. Vogel, et al. 2008 Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial J Natl Cancer Inst 100 542 551 10.1093/jnci/djn085
17. A.S. Caudle A.M. Gonzalez-Angulo K.K. Hunt, et al. 2010 Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer J Clin Oncol 28 1821 1828 10.1200/JCO.2009.25.3286 20231683
18. G. von Minckwitz S. Kummel P. Vogel, et al. 2008 Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study J Natl Cancer Inst 100 552 562 10.1093/jnci/djn089
19. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet 339 8785 71 85
20. D.C. Allred J.M. Harvey M. Berardo G.M. Clark 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 155 168 1:STN:280:DyaK1c7mtlaitg%3D%3D 9504686
21. T. Nemoto J. Vana R.N. Bedwani, et al. 1980 Management and survival of female breast cancer: results of a national survey by the American College of Surgeons Cancer 45 2917 2924 10.1002/1097-0142(19800615)45:12<2917::AID- CNCR2820451203>3.0.CO;2-M 1:STN:280:DyaL3c3it1Cgtg%3D%3D 7388735
22. M. Cristofanilli A. Gonzalez-Angulo N. Sneige, et al. 2005 Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes J Clin Oncol 23 41 48 10.1200/JCO.2005.03.111 15625359
23. S. Dawood K. Broglio S.W. Kau, et al. 2008 Prognostic value of initial clinical disease stage after achieving pathological complete response Oncologist 13 6 15 10.1634/theoncologist.2007-0107 18245008
24. A.U. Buzdar N.K. Ibrahim D. Francis, et al. 2005 Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685 10.1200/JCO.2005.07.032 1:CAS:528:DC%2BD2MXlslWntr8%3D 15738535
25. P.M. Ravdin G.C. Chamness 1995 The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review Gene 159 19 27 10.1016/0378-1119(94)00866-Q 1:CAS:528:DyaK2MXmvFWru78%3D 7607568
26. D.J. Slamon G.M. Clark S.G. Wong, et al. 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 177 182 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D 3798106
27. K.E. Huber L.A. Carey D.E. Wazer 2009 Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy Semin Radiat Oncol 19 204 210 10.1016/j.semradonc.2009.05.004 19732684
28. C.M. Perou T. Sorlie M.B. Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 6797 747 752 10.1038/35021093 1:CAS:528: DC%2BD3cXmt1CnsLw%3D 10963602
29. T. Sorlie C.M. Perou R. Tibshirani, et al. 2010 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 10869 10874 10.1073/pnas.191367098
30. T. Sorlie R. Tibshirani J. Parker, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci U S A 100 8418 8423 10.1073/pnas.0932692100 1:CAS:528:DC%2BD3sXlsFGntLk%3D 12829800
31. C. Sotiriou S.Y. Neo L.M. McShane, et al. 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci U S A 100 10393 10398 10.1073/pnas.1732912100 1:CAS:528:DC%2BD3sXntFynsrk%3D 12917485
32. C. Fan D.S. Oh L. Wessels, et al. 2006 Concordance among gene-expression-based predictors for breast cancer N Engl J Med 355 560 569 10.1056/NEJMoa052933 1:CAS:528:DC%2BD28XotVKnur4%3D 16899776
33. L.A. Carey C.M. Perou C.A. Livasy, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492 2502 10.1001/jama.295.21.2492 1:CAS:528:DC%2BD28XlsV2rtLw%3D 16757721
34. T.O. Nielsen F.D. Hsu K. Jensen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 10.1158/1078-0432.CCR-04-0220 1:CAS:528: DC%2BD2cXmvFSlt7k%3D 15328174
35. M.C. Cheang S.K. Chia D. Voduc, et al. 2009 Ki-67 index, HER-2 status, and prognosis of patients with luminal B breast cancer J Natl Cancer Inst 101 736 750 10.1093/jnci/djp082 1:CAS:528:DC%2BD1MXmtlyit74%3D 19436038
36. V. Guarneri K. Broglio S.W. Kau, et al. 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037 1044 10.1200/JCO.2005.02. 6914 16505422
37. L.A. Carey E.C. Dees L. Sawyer, et al. 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 10.1158/1078-0432.CCR-06-1109 1:CAS:528:DC%2BD2sXkt1enur0%3D 17438091
38. C. Liedtke C. Mazouni K.R. Hess, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 10.1200/JCO.2007.14.4147 18250347
39. R. Rouzier C.M. Perou W.F. Symmans, et al. 2005 Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 5678 5685 10.1158/1078-0432.CCR-04-2421 1:CAS:528:DC%2BD2MXos1Cjs7k%3D 16115903
40. M. Sawaki Y. Ito F. Akiyama, et al. 2006 High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer Breast Cancer 13 172 178 10.2325/jbcs.13.172 16755113
41. L. Gianni M. Zambetti K. Clark, et al. 2005 Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer J Clin Oncol 23 7265 7277 10.1200/JCO.2005.02.0818 1:CAS:528:DC%2BD2MXhtF2nsL3K 16145055
42. J.K. Lee C. Coutant Y.C. Kim, et al. 2010 Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer Clin Cancer Res 1 711 718 10.1158/1078-0432.CCR- 09-2247
43. J.K. Lee D.M. Havaleshko H. Cho, et al. 2007 A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery Proc Natl Acad Sci U S A 104 13086 13091 10.1073/pnas.0610292104 1:CAS:528:DC%2BD2sXpt1Ghtbg%3D 17666531
44. R. Rouzier L. Pusztai S. Delaloge, et al. 2005 Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer J Clin Oncol 23 8331 8339 10.1200/JCO.2005.01. 2898 16293864
45. K.R. Hess K. Anderson W.F. Symmans, et al. 2006 Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer J Clin Oncol 24 4236 4244 10.1200/JCO.2006.05.6861 1:CAS:528:DC%2BD28XhtVGju7vJ 16896004
46. V. Guarneri F. Piacentini G. Ficarra, et al. 2009 A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy Ann Oncol 20 1193 1198 10.1093/annonc/mdn761 1:STN:280:DC%2BD1MvivFWqtQ%3D%3D 19221152
47. R.L. Jones J. Salter R. A'Hern, et al. 2009 The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer Breast Cancer Res Treat 116 53 68 10.1007/s10549-008-0081-7 1:CAS:528:DC%2BD1MXntFaktbY%3D 18592370
48. E.A. Mittendorf Y. Wu M. Scaltriti, et al. 2009 Loss of HER2 amplification following trastuzumabbased neoadjuvant systemic therapy and survival outcomes Clin Cancer Res 15 7381 7388 10.1158/1078-0432.CCR-09-1735 1:CAS:528:DC%2BD1MXhsFSnu7rL 19920100
49. C.J. Creighton X. Li M. Landis, et al. 2009 Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Proc Natl Acad Sci U S A 106 13820 13825 10.1073/pnas.0905718106 1:CAS:528:DC%2BD1MXhtFWksLjF 19666588